Lupin receives Health Canada approval for Rymti

Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis

Football sized rare mesenteric tumour removed laparoscopically at the CK Birla Hospital

In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery

Zydus receives final approval from the USFDA for Ivermectin Cream

Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.

Glenmark Pharma launches Minym Gel for acne treatment

MINYM can be safely used by patients above 9 years of age.

AMPEL BioSolutions' predicts drug options with RNA analytics & machine learning

Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis

Amarex Clinical Research guides its client to phase II of FDA trials

Sanofi Dupixent gets USFDA nod for atopic dermatitis

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood

USFDA accepts dupilumab for priority review in adults with prurigo nodularis

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved

Strides receives USFDA approval for Ibuprofen Oral Suspension

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)

Lancet publishes results of Phase 3 programmes of Rinvoq in Ulcerative Colitis

Data from the three studies formed the basis of the company's application for approval by regulatory agencies